Ambroxol Hydrochloride and Glucose Injection

1 Pharmacological action This product has the characteristics of promoting mucus elimination and dissolving secretions. It can promote the elimination of viscous secretions in the respiratory tract and reduce mucus retention, thereby significantly promoting expectoration and improving respiratory conditions. When this product is used for treatment, the patient's mucus secretion can return to normal. Cough and sputum volume are usually significantly reduced, and the surfactant on the respiratory mucosa can thus play its normal protective function. 4 Toxicological action The toxicity index of ambroxol hydrochloride in acute toxicity tests is very low. Ames test and micronucleus test show that ambroxol hydrochloride is not mutagenic. Carcinogenicity studies in mice and rats show that ambroxol hydrochloride is not carcinogenic.

trans-4-[(2-amino-3,5-dibromobenzyl)amino]cyclohexanol hydrochloride

This product is a colorless clear liquid.

1. Applicable to acute and chronic respiratory diseases accompanied by abnormal sputum secretion and poor sputum function, such as acute exacerbation of chronic bronchitis, asthmatic bronchitis, bronchiectasis and bronchial asthma. 2. Preventive treatment of postoperative pulmonary complications. 4. Treatment of premature infants and neonatal respiratory distress syndrome (IRDS).

Adults and children over 12 years old: 15 mg each time, 2-3 times a day by intravenous drip. In severe cases, the dose can be increased to 30 mg each time; children aged 6-12 years old: 15 mg each time, 2-3 times a day; children aged 2-6 years old: 7.5 mg each time, 3 times a day; children under 2 years old: 7.5 mg each time, 2 times a day. Infants with respiratory distress syndrome: 30 mg/kg/day, divided into 4 doses, with an intravenous infusion time of at least 5 minutes.

This product is well tolerated, with occasional reports of mild upper gastrointestinal side effects, mainly heartburn, indigestion, and occasional nausea and vomiting. Allergic reactions rarely occur, mainly rashes, and severe acute allergic reactions have been reported in very few cases, but their relevance to ambroxol hydrochloride is not certain, and such patients are usually allergic to other substances.

Patients with known allergy to ambroxol hydrochloride or other ingredients of the formula are contraindicated.

Precautions for children: See [Usage and Dosage]. Precautions for pregnancy and lactation: Preclinical experiments and a large amount of clinical experience after 28 weeks of pregnancy show that there is no adverse effect on pregnancy, but the drug should be used with caution during pregnancy, especially in the first three months of pregnancy. The drug can enter breast milk, so it should be used with caution in lactating women. Precautions for the elderly: No special precautions.

When used simultaneously with antibiotics such as amoxicillin, cefuroxime, erythromycin, and doxycycline, the concentration of antibiotics in lung tissue can be increased. Therefore, when this product is used in combination with any of the above drugs to treat lung infections, its antibacterial efficacy can be improved.

Store in an environment below 30℃. Tentatively 1 year

50ml: 30mg of ambroxol hydrochloride and 2.5g of glucose

24 months

Shijiazhuang No.4 Pharmaceutical Co., Ltd.

• Founded in:

  1994-06-28

• Address:

  No. 518, Huaian East Road, Shijiazhuang High-tech Industrial Development Zone

• Tax NO.:

  911301001044060055

• Registered Funds:

  950 million yuan

• Website:

  Log in to view

• Email:

  Log in to view